Sign Up to like & get
recommendations!
1
Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.1081
Abstract: Background Denosumab is a fully human monoclonal antibody (IgG2 subclass) that inhibits bone resorption by inhibiting RANKL, a key mediator of osteoclast formation, function, and survival. Objectives To evaluate the effect of denosumab 60 mg…
read more here.
Keywords:
mitsubishi tanabe;
takeda;
denosumab;
daiichi sankyo ... See more keywords